Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2026 15:00 ET | Source: Oorja Bio

Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases

Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients ORJ-001, set to begin...
May 19, 2026 08:00 ET | Source: Novo Nordisk A/S

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
May 12, 2026 16:05 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
May 12, 2026 09:00 ET | Source: Resolution Therapeutics

Resolution Therapeutics to showcase key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026

Resolution Therapeutics will present key preclinical data today on its RMT RTX001 in an oral presentation at the ASGCT Annual Meeting
May 07, 2026 06:00 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
May 04, 2026 08:47 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
April 28, 2026 02:00 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial

In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight...
March 24, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases.
March 17, 2026 07:00 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

Gyre Therapeutics’ Hydronidone Granted Priority Review Designation in China for CHB-Associated Liver Fibrosis
March 12, 2026 06:00 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update